{"id":3230,"date":"2013-04-15T12:00:00","date_gmt":"2013-04-15T12:00:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/arsredovisning-2012\/"},"modified":"2013-04-15T12:00:00","modified_gmt":"2013-04-15T12:00:00","slug":"arsredovisning-2012","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/arsredovisning-2012\/","title":{"rendered":"\u00c5rsredovisning 2012"},"content":{"rendered":"<\/p>\n<p><span>Idag publicerar XVIVO Perfusion sin svenska \u00e5rsredovisning f\u00f6r 2012. \u00c5rsredovisningen bifogas detta pressmeddelande och den finns \u00e4ven tillg\u00e4nglig p\u00e5 <a href=\"http:\/\/www.xvivoperfusion.com\" rel=\"nofollow\">www.xvivoperfusion.com<\/a>.<\/span><\/p>\n<p><span>En utskriven \u00e5rsredovisning kan best\u00e4llas per telefon 031-788 21 50 eller e-post info@xvivoperfusion.com.<\/span><\/p>\n<\/p>\n<p><span>G\u00f6teborg 15 april 2013<br \/><\/span><span>XVIVO Perfusion AB (publ)<\/span><\/p>\n<\/p>\n<div class=\"mfn-footer\">\n<p><span>F\u00f6r ytterligare information kontakta: <\/span><\/p>\n<p><span>Christoffer Rosenblad, CFO, tel: 031-788 21 59, e-post: <a href=\"mailto:christoffer.rosenblad@xvivperfusion.com\" rel=\"nofollow\">christoffer.rosenblad@xvivoperfusion.com<\/a><br \/>F\u00f6r ytterligare information om Xvivo Perfusions verksamhet h\u00e4nvisas till bolagets hemsida, <a href=\"http:\/\/www.xvivoperfusion.com\" rel=\"nofollow\">www.xvivoperfusion.com<\/a><\/span><\/p>\n<\/p>\n<p><span>XVIVO Perfusion \u00e4r skyldigt att offentligg\u00f6ra informationen i detta pressmeddelande enligt lagen om v\u00e4rdepappersmarknaden och\/eller lagen om handel med finansiella instrument. Informationen l\u00e4mnades f\u00f6r publicering den 15 april 2013 kl. 14:00.<\/span><\/p>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Idag publicerar XVIVO Perfusion sin svenska \u00e5rsredovisning f\u00f6r 2012. \u00c5rsredovisningen bifogas detta pressmeddelande och den finns \u00e4ven tillg\u00e4nglig p\u00e5 www.xvivoperfusion.com&#8230;.<\/p>\n","protected":false},"template":"","class_list":["post-3230","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-vpml","mfn-news-tag-mfn-report","mfn-news-tag-mfn-report-annual"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\u00c5rsredovisning 2012 - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/arsredovisning-2012\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u00c5rsredovisning 2012 - XVIVO\" \/>\n<meta property=\"og:description\" content=\"Idag publicerar XVIVO Perfusion sin svenska \u00e5rsredovisning f\u00f6r 2012. \u00c5rsredovisningen bifogas detta pressmeddelande och den finns \u00e4ven tillg\u00e4nglig p\u00e5 www.xvivoperfusion.com....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/arsredovisning-2012\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/arsredovisning-2012\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/arsredovisning-2012\\\/\",\"name\":\"\u00c5rsredovisning 2012 - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2013-04-15T12:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/arsredovisning-2012\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/arsredovisning-2012\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/arsredovisning-2012\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u00c5rsredovisning 2012\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u00c5rsredovisning 2012 - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/arsredovisning-2012\/","og_locale":"en_US","og_type":"article","og_title":"\u00c5rsredovisning 2012 - XVIVO","og_description":"Idag publicerar XVIVO Perfusion sin svenska \u00e5rsredovisning f\u00f6r 2012. \u00c5rsredovisningen bifogas detta pressmeddelande och den finns \u00e4ven tillg\u00e4nglig p\u00e5 www.xvivoperfusion.com....","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/arsredovisning-2012\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/arsredovisning-2012\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/arsredovisning-2012\/","name":"\u00c5rsredovisning 2012 - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2013-04-15T12:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/arsredovisning-2012\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/arsredovisning-2012\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/arsredovisning-2012\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"\u00c5rsredovisning 2012"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3230","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3230"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}